We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+4.64%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
AUM
$2.53B
AUM Growth
+$68.3M
Cap. Flow
+$49.5M
Cap. Flow %
1.96%
Top 10 Hldgs %
16.36%
Holding
1,009
New
121
Increased
515
Reduced
261
Closed
111

Top Sells

Rank Stock Value
1
OII icon
Oceaneering
OII
+$17.5M
2
ZBRA icon
Zebra Technologies
ZBRA
+$12.8M
3
ISRG icon
Intuitive Surgical
ISRG
+$11.2M
4
IPGP icon
IPG Photonics
IPGP
+$7.17M
5
IRBT
iRobot
IRBT
+$7.11M

Sector Composition

Rank Sector Weight
1 Technology 26.96%
2 Industrials 13.04%
3 Healthcare 11.78%
4 Consumer Discretionary 8.78%
5 Financials 6.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GLW icon
826
Corning
GLW
$143B
$254K 0.01%
9,236
+948
+11% +$26.2K
HI
827
DELISTED
Hillenbrand
HI
$254K 0.01%
5,393
-3,622
-40% -$170K
AVA icon
828
Avista
AVA
$3.24B
$253K 0.01%
4,795
-2,275
-32% -$119K
KWR icon
829
Quaker Houghton
KWR
$2.92B
$253K 0.01%
+1,632
New +$251K
SWKS icon
830
Skyworks Solutions
SWKS
$10.6B
$253K 0.01%
2,621
+451
+21% +$43.8K
TNC icon
831
Tennant Co
TNC
$1.26B
$249K 0.01%
+3,151
New +$236K
NHI icon
832
National Health Investors
NHI
$3.65B
$248K 0.01%
3,362
-3,416
-50% -$241K
JBGS
833
JBG SMITH
JBGS
$708M
$247K 0.01%
+6,765
New +$245K
MDP
834
DELISTED
Meredith Corporation
MDP
$246K 0.01%
4,828
-2,493
-34% -$128K
AGN
835
DELISTED
Allergan plc
AGN
$246K 0.01%
1,476
-2,495
-63% -$401K
RGR icon
836
Sturm, Ruger & Co
RGR
$593M
$244K 0.01%
+4,353
New +$254K
IONS icon
837
Ionis Pharmaceuticals
IONS
$9.4B
$243K 0.01%
5,842
+65
+1% +$2.88K
ADC icon
838
Agree Realty
ADC
$9.41B
$242K 0.01%
+4,592
New +$234K
BBBY
839
Bed Bath & Beyond
BBBY
$442M
$240K 0.01%
+9,481
New +$258K
KNX icon
840
Knight Transportation
KNX
$11.4B
$240K 0.01%
+6,293
New +$259K
PXD
841
DELISTED
Pioneer Natural Resource Co.
PXD
$240K 0.01%
1,271
-851
-40% -$163K
HR
842
DELISTED
Healthcare Realty Trust Incorporated
HR
$240K 0.01%
8,241
-5,117
-38% -$141K
HBAN icon
843
Huntington Bancshares
HBAN
$35.5B
$238K 0.01%
16,114
+2,595
+19% +$39K
ATVI
844
DELISTED
Activision Blizzard
ATVI
$238K 0.01%
3,120
-3,973
-56% -$281K
ILMN icon
845
Illumina
ILMN
$28.4B
$237K 0.01%
874
-1,485
-63% -$378K
TTM
846
DELISTED
Tata Motors Limited
TTM
$236K 0.01%
12,090
-448
-4% -$10.6K
GT icon
847
Goodyear
GT
$1.85B
$235K 0.01%
10,101
+2,547
+34% +$65.4K
AHL
848
DELISTED
ASPEN Insurance Holding Limited
AHL
$235K 0.01%
+5,785
New +$250K
DOC
849
DELISTED
PHYSICIANS REALTY TRUST
DOC
$235K 0.01%
14,760
-167
-1% -$2.52K
PYPL icon
850
PayPal
PYPL
$50.5B
$232K 0.01%
2,789
-7,187
-72% -$573K

Similar funds

Vident Investment Advisory's Q2 2018 Portfolio in Review

As of Q2 2018, Vident Investment Advisory held 1,009 positions worth $2.53B, up 2.8% from $2.46B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Vident Investment Advisory's Q2 2018 filing shows 121 new, 515 increased, 261 reduced and 111 closed positions. Its largest new stake was Arcus Biosciences: 156,139 shares worth $1.91M. The largest sale was Oceaneering, an estimated $17.5M.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Industrials and Healthcare.

  • Vident Investment Advisory's largest Q2 2018 buy was Arcus Biosciences: 156,139 shares worth $1.91M.
  • Vident Investment Advisory added most to State Street SPDR S&P 500 ETF Trust in Q2 2018, an estimated $29.4M increase.
  • Vident Investment Advisory's biggest Q2 2018 reduction was Oceaneering, cutting an estimated $17.5M.
  • Vident Investment Advisory fully exited FIRST TRUST HIGH INCOME LONG/SHORT FUND in Q2 2018, selling an estimated $5.5M.
  • Vident Investment Advisory's ten largest holdings make up 16% of its $2.53B portfolio in Q2 2018.
  • Vident Investment Advisory opened 121 new positions and closed 111 in Q2 2018.
  • Vident Investment Advisory's portfolio value rose 2.8% quarter-over-quarter to $2.53B.

Based on Vident Investment Advisory's 13F filing for Q2 2018, filed 14 Aug 2018.